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Abstract
Background: Some nephrologists have advocated an individualized approach to the prescription of bicarbonate
hemodialysis. However, the utility of monthly serum bicarbonate levels for guiding and evaluating such treatment
decisions has not been evaluated. We sought to define the variability of these measurements and to determine
factors that are associated with month-to-month variability in pre-dialysis serum bicarbonate.
Methods: We examined the monthly variability in serum bicarbonate measurements among 181 hemodialysis
patients admitted to a free-standing dialysis unit in the Bronx, NY from 1/1/2008-6/30/2012. All patients were
treated with a uniform bicarbonate dialysis prescription (bicarbonate 35 mEq/L, acetate 8 mEq/L). Pre-dialysis serum
bicarbonate values were obtained from monthly laboratory reports. Month-to-month variability was defined using a
rolling measurement for each time point.
Results: Only 34 % of high serum bicarbonate values (>26 mEq/L) remained high in the subsequent month,
whereas 60 % converted to normal (22–26 mEq/L). Of all low values (<22 mEq/L), 41 % were normal the following
month, while 58 % remained low. Using the mean 3-month bicarbonate, only 29 % of high values remained high
in the next 3-month period. In multivariable-adjusted longitudinal models, both low and high serum bicarbonate
values were associated with greater variability than were normal values (β = 0.12 (95 % CI 0.09–0.15) and 0.24
(0.18 to 0.29) respectively). Variability decreased with time, and was significantly associated with age, phosphate
binder use, serum creatinine, potassium, and normalized protein catabolic rate.
Conclusions: Monthly pre-dialysis serum bicarbonate levels are highly variable. Even if a clinician takes no action,
approximately 50 % of bicarbonate values outside a normal range of 22–26 mEq/L will return to normal in the
subsequent month. The decision to change the bicarbonate dialysis prescription should not be based on a single
bicarbonate value, and even a 3-month mean may be insufficient.
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Background
Metabolic acidosis is common in patients with end-stage
renal disease (ESRD) receiving hemodialysis (HD) [1–3].
The accumulation of acid in the interdialytic period is
typically neutralized by HD three times per week with a
solution containing a relatively high concentration of
bicarbonate buffer. The therapeutic goal for HD patients
per KDOQI guidelines is to maintain pre-dialysis serum
bicarbonate ≥22 mEq/L [4]. Some would advocate main-
taining pre-dialysis bicarbonate levels higher than
22 mEq/L but below a yet-to-be-defined ceiling because
studies have shown that both metabolic acidosis and
metabolic alkalosis are associated with increased mortal-
ity in this population [1, 2].
One approach to achieving a target level of serum bi-
carbonate is to individualize therapy based on monthly
serum bicarbonate levels [5, 6]. However, well-defined
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protocols are not in widespread use, and the task is
made more difficult by the variety of physiological fac-
tors affecting acid-base balance in ESRD patients [7, 8].
In addition to the effects of nutrition, volume status, and
dialysis adequacy, the delivery of an alkali load may
stimulate organic acid generation in some patients,
thereby mitigating alkalinization [8, 9]. Furthermore,
there may be a great deal of variability in a patient’s bi-
carbonate level from month to month, but this has not
yet been systematically examined. The purpose of this
study is to examine the nature of that variability and
whether patient characteristics and other biomarkers
can predict variability.
We hypothesized that there is substantial intra-
individual variability in monthly serum bicarbonate
levels. To investigate this, we examined monthly labora-
tory data for consecutive patients at one of our affiliated
dialysis units over a 4-year period. All patients received
a uniform dialysis bicarbonate prescription, and no pa-
tients prescribed oral alkali were included. We sought
to define the magnitude of bicarbonate variability and
to determine if this variability was explained by factors
such as dialysis treatment characteristics, markers of




We conducted this retrospective cohort study in an
urban, academically affiliated dialysis center in the
Bronx, NY. All patients at this center were treated with
a uniform bicarbonate dialysis prescription of 35 mEq/L
and a dialysate containing 8 mEq/L acetate during the
study period. Our study cohort consisted of all patients
receiving HD who were admitted to this facility between
January 1, 2008 and June 30, 2012 for at least a 3 month
period and did not meet exclusion criteria. Out of 291
patients admitted during this time period, 74 were ex-
cluded because they did not receive care at this center
for at least three consecutive months, 23 because they
were peritoneal dialysis patients, and 11 due to missing
data. After the exclusion of two patients who were tak-
ing oral sodium bicarbonate, 181 patients were included
in the final cohort, with 4104 monthly observations.
Data collection
Demographic information and medical history were ob-
tained from the patients’ medical records. Information
on medical history and phosphate binder type and dose
was recorded from the monthly progress note, and epoe-
tin alpha administration was recorded from the dialysis
provider’s computerized database. For modeling in re-
gression analyses, phosphate binder use was categorized
based on the number of pills prescribed of an acid-
(sevelamer hydrochloride) or base- (all other binders)
precursor. Information on other prescription medica-
tions was recorded at baseline. Cardiovascular disease
was defined as a history of coronary artery disease,
stroke, peripheral vascular disease, or congestive heart
failure. Laboratory data including serum bicarbonate
levels were obtained from the patients’ monthly pre-
dialysis laboratory reports. In total, 92.6 % of laboratory
data were collected on Monday or Tuesday, per standard
practice in this dialysis unit. As serum bicarbonate
values collected on Monday or Tuesday did not differ
from other days of the week (22.6 ± 3.0 mEq/L Monday/
Tuesday vs. 22.4 ± 3.6 mEq/L other days, p = 0.2), we did
not include the day of sample collection in our analyses.
Ultrafiltration volume was used as a surrogate for inter-
dialytic weight gain (IDWG), which was defined as the
difference between the pre- and post-dialysis weight
after a single monthly HD session. We excluded IDWG
values <0 and >7 kg as we considered these implausible.
Complete data for all covariates of interest was available
for 3833 observations in 180 patients. The study proto-
col was approved by the Institutional Review Board of
the Albert Einstein College of Medicine, which granted a
waiver of informed consent due to the retrospective, ob-
servational design of the study.
Outcome measures
We first examined scatterplots of monthly bicarbonate
values with the bicarbonate value in the subsequent
month, and we calculated the intraclass correlation coef-
ficient (ICC) for serum bicarbonate overall and within
6 month time periods. For comparison with another la-
boratory measure that is highly predictive of clinical out-
comes, we repeated these analyses for serum albumin.
We classified each serum bicarbonate value into clinical
categories using cutpoints that were based on outcomes
data in published epidemiologic studies [1, 2, 10], clinical
practice guidelines [4], and proposals for clinical practice
[3, 11]: low (<22 mEq/L), normal (22–26 mEq/L), and
high (>26 mEq/L). We then examined the likelihood of a
serum bicarbonate value remaining in the same clinical
category on a subsequent month. We repeated this ana-
lysis after categorizing patients based on tertiles of mean
serum bicarbonate in the first 90 days after admission to
the dialysis unit, and within tertiles of the variability
index (Variability Value) defined below. We also calcu-
lated the mean serum bicarbonate during 3-month inter-
vals, categorized these using the same cutpoints, and
calculated the percentage that remained in the same cat-
egory in the subsequent 3-month period.
We quantified the month-to-month variability in
serum bicarbonate by defining a rolling measurement
for each time point i as follows:
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For each patient, we calculated the mean VV of all ob-
servations. The lowest, middle, and highest tertiles of
mean VV were used to classify patients as having low,
medium, and high variability, respectively.
Statistical analysis
Baseline laboratory values were defined as the mean of
all measurements available during the first 90 days after
admission to the dialysis unit. We first characterized the
cohort based on baseline serum bicarbonate values to
determine if the associations in our cohort were consist-
ent with previous reports. Characteristics of the popula-
tion categorized by quartiles of serum bicarbonate were
compared using χ2 for categorical variables and analysis-
of-variance or the Kruskal-Wallis test for continuous
variables.
Mixed-effects models including time as a random ef-
fect were used to examine associations over time of
demographic, clinical, and laboratory characteristics with
serum bicarbonate and VV, separately. As VV did not fit
a Normal distribution, it was log-transformed after add-
ing 1 to the value because VV contained ‘zero’ values:
logVV = ln(VV + 1 mEq/L). Demographics, comorbidi-
ties, dialysis access type, IDWG, phosphate binder and
epoetin alpha prescriptions, and laboratory values re-
lated to nutritional status, inflammation, and dialysis ad-
equacy were included in the models based on a priori
knowledge of the physiology of acid-base regulation in
hemodialysis and previously demonstrated associations
with serum bicarbonate. Medications recorded only at
baseline, dialysis treatment time, blood flow rate, and di-
alysate flow rate were considered for inclusion based on
a p-value <0.20 or >15 % change in other parameters.
The association of each covariate with the outcome was
tested for linearity using higher-order terms and categor-
ical variables; non-linear associations were modeled by
including both linear and quadratic terms in the model,
or with categorical variables. As serum creatinine was
unavailable in one patient, the multivariable models in-
cluded 180 patients. The models were fitted with an in-
dependent variance-covariance structure of the random
effects; using an unstructured covariance matrix did not
change the results. To examine whether the association
of serum bicarbonate level and monthly variability varied
with time, we a priori determined to examine the inter-
action of serum bicarbonate (in clinical categories) with
time in models with logVV as the dependent variable. P
values for interaction with time were not calculated for
other covariates as these were considered exploratory
analyses. Statistical analyses were performed using Stata
software, version 13.1 (Stata Corporation, College




The baseline characteristics of the study participants are
shown in Table 1. The mean age was 56 years, 41 % were
female, and the majority were Black or Hispanic (44 and
40 %, respectively). Comorbidities were common, and
diabetes mellitus was the most common cause of ESRD.
The initial access type was a catheter in 41 % of patients,
although nearly all (62 of 75) eventually transitioned to
either an arteriovenous fistula (AVF) or an arteriovenous
graft (AVG). Phosphate binders were prescribed in 86 %
of patients within 120 days of admission to the dialysis
unit. Only eight patients were never prescribed a phos-
phate binder for the duration of follow-up. The mean
serum bicarbonate during the first 90 days was 23.0 ±
2.2 mEq/L. Smoking status was not recorded for many
patients (39 %). The median follow-up time was
19 months (interquartile range, 10–33) with a range of
4–56 months.
Associations of patient characteristics with serum
bicarbonate levels
In univariate analyses, baseline serum bicarbonate was
not associated with demographics or comorbidities but
differed significantly across quartiles by use of an ACE
inhibitor or ARB. Patients with higher baseline serum bi-
carbonate had less IDWG and lower levels of serum po-
tassium, albumin, phosphate, and normalized protein
catabolic rate (nPCR) (Additional file 1: Table S1).
In longitudinal unadjusted analyses, older age, heart
disease, HD via a tunneled catheter compared to an AVF,
single pool Kt/V (spKt/V) ≥1.71 compared to ≤1.51, and
higher serum calcium were each associated with higher bi-
carbonate levels (Table 2). The highest category of sevela-
mer hydrochloride prescription, greater IDWG, and higher
nPCR, albumin, hemoglobin, serum potassium, phos-
phorus, creatinine, and higher white blood cell (WBC)
counts were associated with lower serum bicarbonate over
time. After multivariable adjustment, the associations with
sevelamer hydrochloride and all laboratory covariates per-
sisted, and there was a significant increase in bicarbonate
levels over time.
Monthly serum bicarbonate variability
The ICC for serum albumin was substantially greater
overall and in each 6-month interval than for serum bi-
carbonate (Table 3). Scatterplots also demonstrated
greater correlation of a monthly measurement with the
subsequent month’s value for serum albumin than for
serum bicarbonate (Fig. 1). We next examined the
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variability of serum bicarbonate measurements in more
detail. Representative plots of serum bicarbonate levels
over time for patients in each of the 3 variability categor-
ies are shown in Fig. 2. Substantial month-to-month
variability is apparent, and appears greatest in the high-
est tertile of VV. Overall, 58 % of low serum bicarbonate
values (<22 mEq/L) remained low in the subsequent
month (Fig. 3, Additional file 1: Table S2). Of all high
values (>26 mEq/L), 60 % were normal the following
month, while only 34 % remained high. Of all normal
values (22–26 mEq/L), 68 % remained normal the fol-
lowing month. These results were largely unchanged
even when examined within tertiles of the 90-day mean
serum bicarbonate (Additional file 1: Figure S1). Only
among patients in the lowest tertile of 90-day mean
serum bicarbonate were low values more likely to re-
main low than to convert to normal the following
month. Regardless of 90-day bicarbonate tertile, high
values were more likely to convert to normal than to re-
main high. Using the mean bicarbonate value over 3-
month time periods, low and normal values were equally
Table 1 Baseline characteristics of 181 hemodialysis patients
Age (years) 56.0 ± 16.6
Female – n (%) 74 (40.9)





Hypertension – n (%) 176 (97.2)
Diabetes Mellitus – n (%) 108 (59.7)
Cardiovascular Disease – n (%) 116 (64.1)
Chronic Obstructive Pulmonary Disease– n (%) 15 (8.3)





Body Mass Index - kg/m2 – n (%)
Underweight (≤18.49) 4 (2.2)
Normal (18.5 – 24.9) 62 (34.3)
Overweight (25 – 29.9) 64 (35.4)
Obese (≥30) 51 (28.2)












Medication use – n (%)
Diuretic 25 (13.8)
ACE inhibitor or ARB 63 (34.8)
Beta blocker 133 (73.5)
Calcium Channel Blocker 109 (60.2)
Statin 93 (51.4)
Proton Pump Inhibitor 51 (28.2)
H2 Blocker 10 (5.5)
Phosphate binder– n (%)a
Sevelamer Hydrochloride 76 (42.0)
Calcium Acetate 38 (21.0)
Sevelamer Carbonate 21 (11.6)
Table 1 Baseline characteristics of 181 hemodialysis patients
(Continued)
Lanthanum Carbonate 6 (3.3)
Calcium Carbonate 6 (3.3)
None 34 (18.8)
Epoetin alpha dose (Units)
≤5000 57 (31.5)
>5000 – ≤10,000 96 (53.0)
≥10,000 28 (15.5)
Interdialytic weight gain (kg) 2.77 ± 0.93
Dialysis treatment time (min) 228.4 ± 18.0
Blood flow rate (mL/min) 382 ± 31
Dialysate flow rate (mL/min) 603 ± 33
Serum bicarbonate (mEq/L)b 23.0 ± 2.2
Serum potassium (mEq/L)b 4.6 ± 0.6
Serum albumin (mg/dL)b 3.7 ± 0.5
Serum calcium (mg/dL)b 8.9 ± 0.6
Serum phosphate (mg/dL)b 5.1 ± 1.2
Serum hemoglobin (g/dL)b 10.8 ± 1.2
Serum creatinine (mg/dL)b 8.0 ± 2.9
WBC (103/mm3)b 7.5 ± 2.1
nPCR (g/kg/day)b 0.82 ± 0.18
spKt/Vb 1.6 ± 0.28
Abbreviations: BMI body-mass index; AVF arteriovenous fistula; AVG arteriovenous
graft; ESRD end-stage renal disease; nPCR normalized protein catabolic rate;
spKt/V single-pool Kt/V; WBC white blood cells
aPhosphate binder data reflect prescriptions within the first 120 days after
admission to the dialysis unit
bLaboratory data are the mean value of all measurements within the first
90 days after admission to the dialysis unit
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Table 2 Longitudinal associations of patient characteristics with serum bicarbonate levels
Unadjusted Multivariable-adjusted
Coefficient (95 % CI) p Coefficient (95 % CI) p
Age (per 10 years) 0.45 (0.29 to 0.61) <0.001 0.07 (−0.10 to 0.25) 0.41
Male −0.54 (−1.12 to 0.05) 0.07 0.09 (−0.45 to 0.63) 0.75
Race/ethnicity
White −0.18 (−1.12 to 0.75) 0.70 −0.61 (−1.45 to 0.23) 0.16
Hispanic/Other −0.44 (−1.06 to 0.17) 0.16 −0.28 (−0.83 to 0.26) 0.31
BMI
Overweight 0.06 (−0.63 to 0.74) 0.87 −0.14 (−0.74 to 0.46) 0.66
Obese −0.01 (−0.74 to 0.72) 0.97 0.16 (−0.48 to 0.80) 0.62
Dialysis access
AVG 0.22 (−0.20 to 0.64) 0.31 −0.18 (−0.60 to 0.24) 0.40
Tunneled catheter 0.33 (0.01 to 0.64) 0.04 0.11 (−0.21 to 0.43) 0.50
Etiology of ESRD
Diabetes 0.50 (−0.20 to 1.21) 0.16 0.38 (−0.26 to 1.02) 0.24
Other/Unknown −0.21 (−1.00 to 0.58) 0.60 0.31 (−0.46 to 1.08) 0.43
Cardiovascular Disease 0.90 (0.31 to 1.48) 0.003 0.41 (−0.18 to 1.01) 0.17
Phosphate binder
>6 pills/day acid precursor −1.00 (−1.45 to−0.55) <0.001 −0.49 (−0.95 to−0.03) 0.04
>3−6 pills/day acid precursor −0.39 (−0.81 to 0.03) 0.07 0.02 (−0.41 to 0.44) 0.9
≤3 pills/day acid precursor 0.002 (−0.38 to 0.39) 0.9 0.27 (−0.13 to 0.66) 0.19
≤3 pills/day base precursor 0.004 (−0.37 to 0.37) 0.9 0.29 (−0.08 to 0.66) 0.12
>3–6 pills/day base precursor 0.04 (−0.35 to 0.43) 0.84 0.36 (−0.04 to 0.75) 0.08
>6 pills/day base precursor −0.23 (−0.61 to 0.15) 0.24 0.08 (−0.33 to 0.49) 0.70
IDW gain (kg)
>1–3 −0.28 (−0.60 to 0.05) 0.10 0.26 (−0.04 to 0.56) 0.08
>3–7 −0.65 (−1.01 to−0.30) <0.001 0.15 (−0.18 to 0.47) 0.38
Epoetin alpha dose (Units)
≤5000 0.11 (−0.11 to 0.32) 0.33 −0.01 (−0.20 to 0.19) 0.9
>5000 – ≤10,000 0.16 (−0.09 to 0.40) 0.16 0.05 (−0.18 to 0.28) 0.69
≥10,000 0.04 (−0.30 to 0.38) 0.83 −0.11 (−0.43 to 0.20) 0.47
spKt/V
1.52–1.70 0.12 (−0.8 to 0.32) 0.25 0.25 (0.06 to 0.44) 0.009
≥1.71 0.31 (0.07 to 0.55) 0.01 0.39 (0.16 to 0.62) 0.001
nPCR (g/kg/day) −3.14 (−3.54 to−2.75) <0.001 −1.08 (−1.52 to −0.64) <0.001
Serum albumin (g/dL) −1.06 (−1.32 to−0.80) <0.001 −0.84 (−1.15 to −0.52) <0.001
Hemoglobin (g/dL) −0.25 (−0.30 to −0.19) <0.001 −0.14 (−0.19 to −0.08) <0.001
K+ (mEq/L) −1.13 (−1.25 to −1.00) <0.001 −0.70 (−0.83 to −0.57) <0.001
Calcium (mg/dL) 0.74 (0.62 to 0.87) <0.001 0.95 (0.82 to 1.08) <0.001
Phosphorus (mg/dL) −0.63 (−0.68 to −0.57) <0.001 −0.39 (−0.45 to −0.32) <0.001
WBC (103/mm3)
6.26–8.25 −0.14 (−0.36 to 0.09) 0.23 0.26 (−0.04 to 0.56) 0.08
≥8.26 −0.35 (−0.64 to −0.08) 0.01 −0.35 (−0.61 to −0.10) 0.007
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likely to remain in the same category (69 and 67 %, re-
spectively), whereas only 29 % of high values remained
high (Fig. 4). When examined within VV tertiles, bicar-
bonate values outside the normal range appeared most
likely to change category among patients with high
variability (i.e. the highest VV tertile) (Additional file 1:
Figure S2).
Associations of patient characteristics with monthly
bicarbonate variability
In multivariable-adjusted longitudinal models, both low
and high serum bicarbonate values were associated with
greater monthly variability (Table 4). Older age and
higher hemoglobin were associated with lower variabil-
ity, and variability decreased with time. Use of an AVG
(compared with AVF), use of epoetin alpha, and higher
serum creatinine were associated with greater variability.
Non-linear associations were noted with nPCR, serum K+,
and calcium, and there was a trend toward lower variabil-
ity with use of any phosphate binder compared with none.
Time-stratified analyses suggested that a number of
associations were modified by time and were not
dependent on the choice of time cutpoint (6 or
12 months) (Table 4, Additional file 1: Table S3). The vari-
ability of low bicarbonate values appeared to decrease with
time, whereas that of high values did not (p = 0.02 for
interaction with time). Male sex was associated with lower
variability only in the early period after dialysis initiation.
A dialysis access other than an AVF and epoetin alpha use
were associated with greater variability, and phosphate
binder use with lower variability, only after 6–12 months
of follow-up. Associations of a number of other laboratory
parameters with variability were modified by time, but not
in a consistent direction.
Discussion
Acid-base homeostasis in dialysis patients is a complicated
process affected by multiple variables, all potentially lead-
ing to marked variation in an individual patient’s pre-
dialysis serum bicarbonate. Indeed, we found significant
variability in monthly serum bicarbonate measurements
among patients receiving HD with a uniform bicarbonate
dialysis prescription, such that a single measurement
Table 2 Longitudinal associations of patient characteristics with serum bicarbonate levels (Continued)
Serum creatinine (mg/dL) −0.33 (−0.37 to −0.29) <0.001 −0.14 (−0.19 to −0.08) <0.001
Time (months) 0.003 (−0.004 to 0.01) 0.40 0.02 (0.01 to 0.03) <0.001
Abbreviations: CI confidence interval; BMI body-mass index; AVG arteriovenous graft; ESRD end-stage renal disease; ACE-I angiotensin-converting enzyme inhibitor;
ARB angiotensin receptor blocker; nPCR normalized protein catabolic rate; spKt/V single-pool Kt/V; WBC white blood cells; IDW interdialytic weight gain
Models included all variables listed in the Table. Reference categories are female for sex; Black for race/ethnicity; normal/underweight for BMI; arteriovenous
fistula (AVF) for dialysis access; hypertension for etiology of ESRD; no binder use for phosphate binder; no epoetin alpha use for epoetin alpha dose; 0-1 kg for
interdialytic weight gain; ≤1.51 for spKt/V; ≤6.25 103/mm3 for WBC. Bold values indicate p<0.05.












Overall 181 4104/4099 0.38 0.68
0–6 months 181 1160/1156 0.34 0.68
>6–12 months 156 849/849 0.47 0.74
>12–18 months 117 609/609 0.51 0.78
>18–24 months 93 526/525 0.53 0.80
>24–30 months 70 373/373 0.57 0.73
>30–36 months 53 277/277 0.41 0.64
>36 months 36 310/310 0.54 0.61
Fig. 1 Scatterplots demonstrating the correlation of consecutive
monthly measurements. Scatterplots showing the correlation of a
monthly measurement (x-axis) with the subsequent monthly
measurement (y-axis) for serum bicarbonate (top panel) and
serum albumin (bottom panel)
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considered high or low based on clinical cutpoints is of lit-
tle value. Importantly, there were no changes to patients’
dialysis prescriptions, provision of oral alkali, or changes
in phosphate binder in response to these monthly labora-
tory values. Therefore, even if a clinician takes no action,
approximately 50 % of bicarbonate values outside a
normal range of 22–26 mEq/L will return to normal in
the subsequent month. Using the mean value over
3 months modestly improves the predictive ability of low
values, but not high ones. Regardless, even under the best














































































Fig. 3 Predicting next month’s bicarbonate level. For a single monthly serum bicarbonate measurement falling within the low (<22 mEq/L),
normal (22–26 mEq/L), and high (>26 mEq/L) categories defined by clinical cutpoints, the percentage of measurements in the following month
that remain in the same category or change category are shown. Percentages may not sum to exactly 100 % due to rounding















Fig. 2 Sample plots demonstrating levels of variability. Representative graphs of serum bicarbonate over time are shown for 3 patients in each of
the 3 variability categories. Low, medium, and high variability were defined based on tertiles of the mean value of VV (Variability Value) for each
patient during follow-up: Low (mean VV ≤2.18 mEq/L), Medium (mean VV = 2.19 to 2.75 mEq/L), and High (mean VV ≥2.76 mEq/L)
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circumstances, at least one-third of monthly or quarterly
mean bicarbonate levels will change category with the
next measurement. By comparison, consecutive monthly
measurements of serum albumin, which is highly predict-
ive of outcomes in ESRD patients [12] and is used to diag-
nose protein-energy wasting [13], were much more highly
correlated.
This has clear implications for any intervention aimed
at changing a hemodialysis patient’s metabolic acid-base
status. First, the decision to intervene to raise or lower
the serum bicarbonate should not be based on a single
bicarbonate value, and even a 3-month mean may be
insufficient. Second, if relying on monthly laboratory
reports to determine the outcome, at least three mea-
surements are required to reliably determine an effect.
Thus, individualization of the dialysis prescription is a
complex endeavor, and was not associated with im-
proved mortality in a recent analysis of an international
cohort [14]. Knowledge of a patient’s prior variability
may inform the decision to intervene.
In our cohort, serum bicarbonate was inversely associ-
ated with several nutritional parameters. This is consist-
ent with previous reports in HD patients which indicate
that serum bicarbonate is partly determined by dietary
intake and is a marker for nutritional status in ESRD pa-
tients [1, 2, 15–17]. Thus, one would expect that the
variability in monthly serum bicarbonate measures
would be related to patient nutrition. Our data point to
non-linear associations of several nutritional parameters
with bicarbonate variability, suggesting that patients at
both ends of the nutritional spectrum exhibit the greatest
variability. Although we also hypothesized that dialysis ad-
equacy and interdialytic weight gain would be important
determinants of bicarbonate variability, our findings did
not support this. The lack of an association with Kt/V
may be due to confounding by body size, which would
also determine the volume of distribution of bicarbonate.
Similarly, residual confounding related to nutritional fac-
tors and medication compliance may explain the lack of
an association with interdialytic weight gain. Alternatively,
the use of ultrafiltration volume as a surrogate for IDWG
may have introduced imprecision into the measure and
limited our ability to detect an association.
A number of previous studies have reported lower
serum bicarbonate values with sevelamer hydrochloride
use [18–21]. In our cohort, patients taking >6 pills per
day of sevelamer hydrochloride had lower bicarbonate
levels over time compared with no binder use, and there
was a trend toward higher bicarbonate levels in patients
taking binders containing base precursors. Binder use,
regardless of type, was associated with lower variability
over time. We hypothesize that binder use reduced bi-
carbonate variability by increasing the fraction of dietary
acid that did not change from month to month.
We also noted an association of access type with
monthly bicarbonate variability. The results of the time-
stratified models suggest that use of an access other than
an AVF is associated with greater variability, and that
after 12 months, catheter use may be associated with the
greatest variability. Access-related issues that affect dia-
lysis adequacy and could also lead to missed treatments
and hospitalizations are the most likely explanation for







































































Fig. 4 Predicting the next 3-month mean serum bicarbonate level. For each mean serum bicarbonate calculated over a 3-month period and
falling within the low (<22 mEq/L), normal (22–26 mEq/L), and high (>26 mEq/L) categories defined by clinical cutpoints, the percentage of mean
values in the following 3-month period that remain in the same category or change category are shown. Percentages may not sum to exactly
100 % due to rounding
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Table 4 Multivariable-adjusted associations of clinical and laboratory characteristics with serum bicarbonate variability over time
Overall ≤12 months >12 months
Coefficient (95 % CI) p Coefficient (95 % CI) p Coefficient (95 % CI) p
Age (per 10 years) −0.03 (−0.04 to −0.01) 0.009 −0.03 (−0.05 to 0.00) 0.03 0.00 (−0.03 to 0.03) 0.9
Male −0.04 (−0.09 to 0.02) 0.19 −0.09 (−0.16 to −0.01) 0.02 0.02 (−0.05 to 0.09) 0.65
Race/ethnicity
White −0.03 (−0.11 to 0.06) 0.53 −0.03 (−0.13 to 0.08) 0.64 −0.07 (−0.17 to 0.04) 0.22
Hispanic/Other −0.03 (−0.09 to 0.03) 0.31 −0.04 (−0.11 to 0.03) 0.24 0.00 (−0.07 to 0.08) 0.9
BMI
Overweight 0.01 (−0.05 to 0.07) 0.78 0.02 (−0.06 to 0.09) 0.65 0.02 (−0.05 to 0.10) 0.56
Obese −0.02 (−0.09 to 0.04) 0.52 −0.01 (−0.09 to 0.07) 0.83 −0.01 (−0.10 to 0.07) 0.77
Dialysis access
AVG 0.06 (0.00 to 0.11) 0.04 0.01 (−0.06 to 0.09) 0.75 0.07 (0.00 to 0.14) 0.04
Tunneled catheter 0.04 (−0.01 to 0.09) 0.15 0.00 (−0.07 to 0.07) 0.9 0.19 (0.09 to 0.28) <0.001
Etiology of ESRD
Diabetes −0.03 (−0.09 to 0.04) 0.41 −0.04 (−0.12 to 0.04) 0.33 0.03 (−0.06 to 0.11) 0.54
Other/Unknown −0.06 (−0.14 to 0.01) 0.11 −0.08 (−0.18 to 0.01) 0.09 0.00 (−0.09 to 0.10) 0.9
Cardiovascular Disease 0.05 (−0.01 to 0.11) 0.13 0.06 (−0.02 to 0.13) 0.13 0.04 (−0.04 to 0.11) 0.32
Phosphate binder
>6 pills/day acid precursor −0.03 (−0.11 to 0.05) 0.50 0.05 (−0.07 to 0.17) 0.39 −0.09 (−0.21 to 0.04) 0.19
>3–6 pills/day acid precursor −0.05 (−0.12 to 0.03) 0.21 0.04 (−0.07 to 0.14) 0.50 −0.12 (−0.25 to 0.01) 0.06
≤3 pills/day acid precursor −0.09 (−0.16 to −0.02) 0.01 −0.06 (−0.15 to 0.02) 0.16 −0.12 (−0.24 to 0.01) 0.07
≤3 pills/day base precursor −0.04 (−0.11 to 0.02) 0.21 −0.02 (−0.10 to 0.06) 0.60 −0.06 (−0.18 to 0.06) 0.31
>3–6 pills/day base precursor −0.07 (−0.14 to 0.00) 0.07 0.00 (−0.10 to 0.09) 0.95 −0.14 (−0.26 to −0.01) 0.03
>6 pills/day base precursor −0.08 (−0.15 to 0.00) 0.04 −0.06 (−0.16 to 0.05) 0.30 −0.11 (−0.23 to 0.01) 0.07
Epoetin alpha dose (Units)
≤5000 0.05 (0.02 to 0.09) 0.005 −0.02 (−0.07 to 0.04) 0.57 0.10 (0.05 to 0.15) <0.001
>5000 – ≤10,000 0.03 (−0.02 to 0.07) 0.23 0.01 (−0.05 to 0.07) 0.81 0.03 (−0.04 to 0.09) 0.44
≥10,000 0.06 (0.00 to 0.12) 0.04 −0.02 (−0.10 to 0.06) 0.65 0.16 (0.07 to 0.25) <0.001
Serum bicarbonate (mEq/L)
<22 0.12 (0.09 to 0.15) <0.001 0.17 (0.13 to 0.22) <0.001 0.08 (0.03 to 0.12) 0.001
>26 0.24 (0.18 to 0.29) <0.001 0.23 (0.16 to 0.31) <0.001 0.25 (0.18 to 0.32) <0.001
Serum albumin (g/dL) 0.03 (−0.02 to 0.09) 0.25 0.07 (0.00 to 0.15) 0.04 −0.04 (−0.13 to 0.04) 0.32
nPCR (g/kg/day) −0.42 (−0.73 to −0.10) 0.009 −0.23 (−0.80 to 0.33) 0.42 −0.46 (−0.84 to −0.07) 0.02
nPCR2 ((g/kg/day)2) 0.19 (0.04 to 0.34) 0.01 0.09 (−0.20 to 0.37) 0.55 0.21 (0.04 to 0.38) 0.02
spKt/V 0.04 (−0.02 to 0.10) 0.18 0.04 (−0.04 to 0.11) 0.35 0.04 (−0.04 to 0.12) 0.34
K+ (mEq/L) −0.18 (−0.36 to 0.00) 0.05 −0.10 (−0.36 to 0.16) 0.47 −0.23 (−0.48 to 0.02) 0.07
K+2 ((mEq/L)2) 0.02 (0.00 to 0.04) 0.05 0.01 (−0.02 to 0.03) 0.49 0.02 (0.00 to 0.05) 0.05
Hemoglobin (g/dL) −0.02 (−0.03 to −0.01) 0.002 −0.04 (−0.05 to −0.02) <0.001 0.00 (−0.02 to 0.02) 0.9
Calcium (mg/dL) −0.34 (−0.57 to −0.12) 0.003 −0.48 (−0.74 to −0.22) <0.001 −0.09 (−0.55 to 0.38) 0.71
Calcium2 ((mg/dL)2) 0.02 (0.01 to 0.03) 0.002 0.03 (0.01 to 0.04) <0.001 0.01 (−0.02 to 0.03) 0.65
Phosphorus (mg/dL) 0.01 (0.00 to 0.02) 0.09 0.00 (−0.02 to 0.01) 0.64 0.03 (0.01 to 0.04) <0.001
Serum creatinine (mg/dL) 0.01 (0.00 to 0.02) 0.03 0.01 (0.00 to 0.02) 0.19 0.01 (0.00 to 0.02) 0.11
WBC (103/mm3) 0.01 (0.00 to 0.01) 0.17 0.01 (0.00 to 0.02) 0.13 0.00 (−0.01 to 0.01) 0.79
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these findings. Access type, especially catheter use, could
also be a marker for patients with poorer or more vari-
able nutritional status.
We cannot account for the amount of variability due
to sample handling and delays in measurement [22, 23].
However, this is unlikely to account for all the variability
that we observed. Values measured at a central labora-
tory may be falsely low for a variety of reasons [24], al-
though it has been suggested that this is a rare event
[25]. Also, if falsely low values occurred frequently, we
might expect to see the greatest variability among low
serum bicarbonate measurements, but in our cohort
high values were associated with the highest variability
in multivariable analyses and were the least likely to be
confirmed on a subsequent measurement. Furthermore,
the independent associations of several clinical and la-
boratory values with bicarbonate variability suggest that
patient-level factors contribute as well. Simultaneous
measurement in a local laboratory would nevertheless
have provided a useful comparison. Regardless, our find-
ings remain clinically relevant to the day-to-day practice
of managing patients’ dialysis prescriptions as providers
rely on the monthly laboratory reports as the only data
to guide their clinical decision-making.
Several other limitations should be noted. Data were
not available for residual renal function, which could ex-
plain some of the decline in variability over time. Phos-
phate binder prescriptions were included in our models
but without information on medication adherence. We
could not account for any effect of dialysis shift in our
analyses, nor did we have information on treatment ad-
herence. Few data were available regarding respiratory
function, but as there would be little or no metabolic
compensation, the effect on serum bicarbonate would be
minor. Lastly, the dietary patterns of our patients may
not generally reflect other geographical regions and
could limit the generalizability of our findings.
A number of additional questions remain unanswered.
The magnitude of variability should be verified in larger
cohorts, along with further examination of the effect of
early and late dialysis vintage on variability. Future studies
should also use local lab measurements to determine how
much variability is accounted for by measurement error. It
will be important to determine whether bicarbonate vari-
ability changes around the time of a hospitalization, and
whether variability is predictive of outcomes. Finally, a
more detailed understanding of the role of organic anion
generation and other physiologic factors in modulating bi-
carbonate variability is needed [8].
Conclusions
The pre-dialysis serum bicarbonate values on monthly la-
boratory reports in hemodialysis patients are highly vari-
able. Further study is needed before they can be relied on
as the basis for clinical intervention, especially as this re-
lates to correcting high values.
Additional file
Additional file 1: Table S1. Baseline characteristics by quartiles of
baseline serum bicarbonate. Table S2. Transition matrix showing the
number of serum bicarbonate measurements in a clinical category in a
given month and in the subsequent month. Figure S1. Predicting next
month’s serum bicarbonate level, within tertiles of 90-day mean serum
bicarbonate. For a single monthly serum bicarbonate measurement falling
within the low (<22 mEq/L), normal (22–26 mEq/L), and high (>26 mEq/L)
categories defined by clinical cutpoints, the percentage of measurements in
the following month that remain in the same category or change category
are shown within tertiles of the mean serum bicarbonate during the first
90 days after admission to the dialysis unit: ≤22 mEq/L (n = 62), 22.25 –
24 mEq/L (n = 65), ≥24.25 mEq/L (n = 54). Percentages may not sum to
exactly 100 % due to rounding. Figure S2. Predicting next month’s serum
bicarbonate level, within tertiles of variability value. For a single monthly
serum bicarbonate measurement falling within the low (<22 mEq/L),
normal (22–26 mEq/L), and high (>26 mEq/L) categories defined by clinical
cutpoints, the percentage of measurements in the following month that
remain in the same category or change category are shown within tertiles
of the mean value of VV (Variability Value) for each patient during follow-up:
Table 4 Multivariable-adjusted associations of clinical and laboratory characteristics with serum bicarbonate variability over time
(Continued)
IDW gain (kg)
>1–3 0.01 (−0.05 to 0.07) 0.8 −0.03 (−0.12 to 0.05) 0.41 0.04 (−0.05 to 0.12) 0.38
>3–7 0.02 (−0.04 to 0.09) 0.48 −0.03 (−0.12 to 0.06) 0.55 0.07 (−0.02 to 0.15) 0.15
Time (months)
>3–6 −0.05 (−0.11 to 0.00) 0.04 −0.05 (−0.11 to 0.00) 0.06 ….
>6–12 −0.09 (−0.14 to −0.04) <0.001 −0.10 (−0.15 to −0.04) 0.001 ….
>12–24 −0.12 (−0.18 to −0.07) <0.001 …. ref
>24 −0.14 (−0.20 to −0.07) <0.001 …. 0.00 (−0.04 to 0.04) 0.88
Abbreviations: CI confidence interval; BMI body-mass index; AVG arteriovenous graft; ESRD end-stage renal disease; nPCR normalized protein catabolic rate; spKt/V
single-pool Kt/V; WBC white blood cells; IDW interdialytic weight gain
Models included all variables listed in the Table. Reference categories are female for sex; Black for race/ethnicity; normal/underweight for BMI; arteriovenous
fistula (AVF) for dialysis access; hypertension for etiology of ESRD; no binder use for phosphate binder; no epoetin alpha use for epoetin alpha dose;
22–26 mEq/L for serum bicarbonate; 0–1 kg for interdialytic weight gain; ≤3 months for time in the Overall and ≤12 months models, and >12–24 months in
the >12 months model. Bold values indicate p<0.05.
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Low (mean VV ≤2.18 mEq/L), Medium (mean VV = 2.19 to 2.75 mEq/L), and
High (mean VV ≥2.76 mEq/L). Percentages may not sum to exactly 100 %
due to rounding. Table S3. Multivariable-adjusted associations of clinical
and laboratory characteristics with serum bicarbonate variability over time
within and after the first 6 months. (DOCX 67 kb)
Abbreviations
AVF: Arteriovenous fistula; AVG: Arteriovenous graft; ESRD: End-stage renal
disease; HD: Hemodialysis; ICC: Intraclass correlation coefficient;
IDWG: Interdialytic weight gain; nPCR: Normalized protein catabolic rate;
spKt/V: Single pool Kt/V; VV: Variability value; WBC: White blood cell.
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